Study of TGW101 for Advanced Solid Tumors
This study is testing a new treatment called TGW101 for people with advanced solid tumors. TGW101 is a combination of two parts: TGW101-ADC and TRG001, which are given separately. The main goals are to see how safe TGW101 is, what side effects it might cause, and to find the best dose. Researchers will also look at how the body handles TGW101 and if it shows any early signs of helping against cancer. You may be able to join if you are 18 or older and have a solid tumor that has progressed. The study is currently unclear about its recruitment status.
- Study design
- This is an interventional study with a planned enrollment of 50 participants. It aims to evaluate the safety, tolerability, and preliminary effectiveness of TGW101.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be monitored for adverse events and cycle delays for up to approximately 10 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
At a glance
Conditions
Where it's being run
7 sites across 5 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Participants Experiencing Adverse Events (AEs)Up to approximately 10 months
- Number of Participants Experiencing Dose-limiting Toxicities (DLTs)Up to Day 21
- Number of Participants Experiencing Cycle DelayUp to approximately 10 months
- Number of Participants Experiencing Dose ReductionUp to approximately 10 months
- RDE of TGW101Up to approximately 10 months